Current Investments
Nabriva Therapeutics AG
David Chiswell, Vienna, AT
Nabriva is a specialist antibiotic company with the objective of discovering and developing innovative antibacterials positioned to battle antibiotic resistance in Gram-positive and Gram-negative pathogens.
NanoPowers AG
Martin Horst, Lausanne, CH
NanoPowers aims to develop artificial muscles for various implant indications. The Company has developed several animal proof of concepts, and is entering preclinical stages with devices aimed for the treatment of urinary and fecal incontinences.
Neomics Co. Ltd.
Chiuk In, Seoul, South Korea
Neomics develops novel therapeutics with applications in oncology and tissue regeneration.
Neovacs SA
Guy-Charles Fanneau de La Horie, Paris, FR
NeoVacs SA is a Paris based vaccine company pioneering the next generation of anti-body therapies against human cytokines with a novel active immunization approach. Its innovative platform is used to develop vaccine products that are inducing e.g. an anti-TNFα, anti-VEGF and anti-IFNα polyclonal responses, and that are targeting broad pharmaceutical markets.
Nereus Pharmaceuticals Inc.
Kobi M. Sethna, San Diego, CA, US
Nereus pursues untapped sources of chemical diversity which together with it’s expertise in marine microbiology and integrated technologies enabled the identification and development of two oncology drug candidates which are in Phase I clinical trials.
NovImmune AG
Jack Barbut, Geneva, CH
NovImmune is a drug development company focusing on immune mechanisms targeted to inflammation. NovImmune has a portfolio of fully human therapeutic monoclonal antibodies in development, including NI-0501 and NI-0401 (anti-CD3) at Ph IIa.